|
|
Prohost Biotechnology OnlineThe Newsletter of Biotechnology Research and Investment |
|
|
|
Conference CallUrsiteisgoodFrom: LovingU Comments<a href=http://www.jipiaovip.com>»úƱ,ÌؼۻúƱ,¹ú¼Ê»úƱ,ÌؼۻúƱ</a> [url=http://www.jipiaovip.com]»úƱ,ÌؼۻúƱ,¹ú¼Ê»úƱ,ÌؼۻúƱ[/url [url=http://www.jipiaovip.com/cd]³É¶¼»úƱ[/url [url=http://www.jipiaovip.com/cd/cdtjjp]³É¶¼ÌؼۻúƱ[/url [url=http://www.datangfly.com/cd]³É¶¼»úƱ[/url [url=http://www.jipiaovip.com/cd/cddzjp]³É¶¼´òÕÛ»úƱ[/url [url=http://www.jipiaovip.com/bj]±±¾©»úƱ[/url [url=http://www.jipiaovip.com/bj/bjtjjp]±±¾©ÌؼۻúƱ[/url [url=http://www.jipiaovip.com/bj/bjdzjp]±±¾©´òÕÛ»úƱ[/url [url=http://www.jipiaovip.com/bj/bjgjjp]±±¾©¹ú¼Ê»úƱ[/url [url=http://www.jipiaovip.com/sh]ÉϺ£»úƱ[/url [url=http://www.jipiaovip.com/sh/shtjjp]ÉϺ£ÌؼۻúƱ[/url [url=http://www.jipiaovip.com/sh/shdzjp]ÉϺ£´òÕÛ»úƱ[/url [url=http://www.jipiaovip.com/gz]¹ãÖÝ»úƱ[/url [url=http://www.jipiaovip.com/gz/gztjjp]¹ãÖÝÌؼۻúƱ[/url [url=http://www.jipiaovip.com/gz/gzdzjp]¹ãÖÝ´òÕÛ»úƱ[/url [url=http://www.jipiaovip.com/hz]º¼ÖÝ»úƱ[/url [url=http://www.jipiaovip.com/hz/hztjjp]º¼ÖÝÌؼۻúƱ[/url [url=http://www.jipiaovip.com/hz/hzdzjp]º¼ÖÝ´òÕÛ»úƱ[/url [url=http://www.jipiaovip.com/cq]ÖØÇì»úƱ[/url [url=http://www.jipiaovip.com/cq/cqtjjp]ÖØÇìÌؼۻúƱ[/url [url=http://www.jipiaovip.com/cq/cqdzjp]ÖØÇì´òÕÛ»úƱ[/url [url=http://www.jipiaovip.com/fz]¸£ÖÝ»úƱ[/url [url=http://www.jipiaovip.com/fz/fztjjp]¸£ÖÝÌؼۻúƱ[/url [url=http://www.jipiaovip.com/fz/fzdzjp]¸£ÖÝ´òÕÛ»úƱ[/url [url=http://www.jipiaovip.com/sy]ÉòÑô»úƱ[/url [url=http://www.jipiaovip.com/sy/sytjjp]ÉòÑôÌؼۻúƱ[/url [url=http://www.jipiaovip.com/sy/sydzjp]ÉòÑô´òÕÛ»úƱ[/url AVANIR Pharmaceuticals Added to Russell 2000 and 3000 IndexesFrom: JimmyZ CommentsAVANIR Pharmaceuticals Added to Russell 2000 and 3000 Indexes Tuesday July 10, 7:03 am Eastern Time Press Release SOURCE: AVANIR Pharmaceuticals AVANIR Pharmaceuticals Added to Russell 2000 and 3000 Indexes SAN DIEGO, July 10 /PRNewswire/ -- AVANIR Pharmaceuticals (Amex: AVN - news) today announced that it has been added to the list of companies making up Frank Russell Company's Russell 2000® and Russell 3000® Indexes. ``AVANIR's inclusion in the Russell 2000 and Russell 3000 Indexes represents a significant achievement by the company and, more importantly, an acknowledgement of the value we have been able to create at AVANIR and our future prospects,'' stated Gerald J. Yakatan, Ph.D., President and CEO of AVANIR. ``We have achieved a number of important corporate milestones in the last year intended to build shareholder value, and we are pleased to join the select group of companies included in the Russell Indexes.'' Frank Russell Company compiles and maintains 21 U.S. equity indexes that are market cap-weighted and include only common stocks domiciled in the United States and its territories. The Russell Indexes are widely used as performance benchmarks for measuring fund and investment performance. Frank Russell Company reports that more than $180 billion is invested in funds modeling Russell's U.S. indexes and more than $1 trillion in funds is benchmarked against the indexes globally. Frank Russell Company formally released on July 9, 2001 at 5:00 p.m. Pacific Time the listing of Index members, which is effective for the period from July 1, 2001 to June 30, 2002. AVANIR Pharmaceuticals, based in San Diego, is an emerging diversified biopharmaceutical company engaged in research, development, commercialization, licensing and sales of innovative drug products and antibody generation services. The Company's website is www.avanir.com. The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the Company's Annual Report on Form 10-K and other publicly available information regarding the Company, copies of which are available from the Company upon request. Such publicly available information sets forth many risks and uncertainties related to AVANIR's business and technology, including risks and uncertainties related to drug development and clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trials results are unpredictable and outside of the influence and/or control of the Company. The Company is not affiliated with The Frank Russell Company. Further, AVANIR's inclusion in the Russell 2000 and 3000 Indexes should not imply that the Company's stock price performance will be any better or worse than what it would have been without being included in the indexes. SOURCE: AVANIR Pharmaceuticals From: DigitalJam2000 CommentsI just listened to Joseph Reiser, Ph.D., Cytogen's Chief Executive Officer on the conference call. The impression I got was that this company is getting positioned for the long term. It seems that Axcell will have not only the fastest protenomic database but also the smartest one with "Less false positive results". As long as Axcell keeps mapping protein interactions and then REGISTERING DOMAINS, they will not only have a market advantage...they will eventually have the entire market. Let's not forget PMSA Reiser's comments indicated that the market for PMSA related treatment could reach several billion, and the market for PMSA related diagnostics could reach high hundreds of millions. Let's not forget ProstaScint(R) and OncoScint(R) "We expanded the potential revenue base for our approved products by obtaining international marketing rights and by increasing our control of marketing and sales" Let's not forget Quadramet(R) "Quadramet was launched by Berlex Laboratories in early 1999. Gross sales for 1999 increased 51% over 1998. Cytogen developed Quadramet and receives a royalty on sales" This is a good time for all the weak hands to fold and those that believe in this company to hold on for a great year ahaid.
|
|
